Actively Recruiting
Evaluating Tofacitinib Treatment for Juvenile Idiopathic Arthritis Using Real-World Clinical Data
Led by Consorci Sanitari de l'Alt Penedès i Garraf · Updated on 2026-10-28
58
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of tofacitinib in children and adolescents under 18 years old diagnosed with juvenile idiopathic arthritis JIA. The study aims to understand how effective tofacitinib is in improving disease control over a 12-month period using real-world clinical data. This observational study is led by the Consorci Sanitari de lAlt Peneds i Garraf. Participants in this study are those with JIA who have been prescribed tofacitinib as part of their treatment. The study does not assign treatment but observes patients already using tofacitinib in routine clinical practice. The main focus is on monitoring clinical outcomes over the course of one year after starting tofacitinib. During the study, researchers will review medical records and clinical data to assess disease activity using the Juvenile Arthritis Disease Activity Score JADAS-10 at the start and after 12 months of treatment. No additional interventions are administered as part of the study. Participants ongoing care continues with their usual healthcare providers, and the study monitors outcomes based on standard clinical assessments documented in regular practice.
CONDITIONS
Brief Title
Tofacitinib in Juvenile Idiopathic Arthritis
Research Team
N
Noemí Casaponsa
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here